Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Vitiligo is a common, psychologically devastating condition that causes skin to lose its pigmentation or color. Current treatments, such as steroid creams and light therapy, are not reliably effective in reversing the disease. A new study says, a drug used for treating rheumatoid arthritis has restored skin color in a female patient suffering from vitiligo -- a common, skin condition where portion of skin loses its pigmentation or color. The report was published in JAMA Dermatology.

  • Jubilant Life Sciences' receives ANDA approval for levofloxacin tablets

    Jubilant Life Sciences Ltd, an integrated global pharmaceuticals and life sciences company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for levofloxacin tablets, 250mg and 500mg. It is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.

  • Wockhardt has received final approval from the US FDA for marketing 5mg/5ml of oxycodone HCI liquid. The company is launching the product soon and will be amongst the few generic versions of this product in the market.

  • Researchers from the Laboratory of Cancer Metabolism at IDIBELL found a potential target for the treatment of type 2 diabetes. The study is published in the Journal of Clinical Investigation. Research led by Sara Kozma, have shown in animal models that inhibition of S6K1 protein may be a potential treatment for type 2 diabetes.

  • Nearly 700,000 people around the world die from colorectal cancer each year. Colorectal cancer is the second leading cause of cancer-related death in developed countries.  Anti-cancer therapies generally involve killing off tumor cells. A new study says, now the cancer cells can be turned back into normal tissue simply by reactivating a single gene.  The study is published in the Cell.

    [adsense:336x280:8701650588]

  • Aurobindo Pharma got final approvals from the US FDA of azithromycin for injection USP, 500mg /vial and entacapone tablets. Azithromycin for injection USP, 500mg/vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (azithromycin for injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as community-acquired pneumonia and pelvic inflammatory disease.

  • Australian researchers have developed a breakthrough vaccine-style therapeutic approach to treat rheumatoid arthritis, a debilitating disease affecting over 450,000 people in the country. Lead researcher Ranjeny Thomas from the University of Queensland's Diamantina Institute said results from the phase one clinical trial demonstrate the new treatment is safe and effective in supressing the immune response.

  • The research conducted by Dundee University, Scotland explained that the newly developed drug could work well against parasites resistant to current treatments of the mosquito-borne disease. Researchers  discovered a new compound, DDD107498 to treat malaria in a single dose, protects people from the disease and prevent the transmission of infection. The research is printed  in the journal 'Nature'.

Subscribe to Pharma News